Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
4.35
Oct 26 • 3:59 PM ET Dollar change-4.14 Percentage change(-48.76%)
Aftermarket Close
4.33
Aftermarket • 7:59 PM ET Dollar change-0.02 Percentage change(-0.49%)
Oct 26, 4:45 PMCumberland Pharmaceuticals to submit NDA for ifetroban in Duchenne muscular dystrophy–associated cardiomyopathy as FDA grants rolling review
Index
-
Market Cap
65.18M
Enterprise Value
65.70M
Income
-10.92M
Sales
31.27M
Book/sh
1.16
Cash/sh
0.26
Employees
93
IPO
Aug 11, 2009
P/E
-
Forward P/E
-
PEG
-
P/S
2.08
P/B
3.74
P/C
16.89
P/FCF
95.85
EV/EBITDA
-
EV/Sales
2.10
Quick Ratio
0.96
Current Ratio
0.96
Debt/Eq
0.27
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
-0.73
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
20.68% 2.82%
Sales past 3/5Y
1.95% 3.52%
EPS Y/Y TTM
-244.92%
Sales Y/Y TTM
-25.68%
EPS Q/Q
-476.57%
Sales Q/Q
-98.46%
Insider Own
41.60%
Insider Trans
0.00%
Inst Own
16.57%
Inst Trans
-6.85%
ROA
-14.91%
ROE
-42.92%
ROIC
-50.43%
Gross Margin
86.22%
Oper. Margin
-29.58%
Profit Margin
-34.92%
SMA20
-40.43%
SMA50
-40.86%
SMA200
-9.02%
Trades
Shs Outstand
14.98M
Shs Float
8.75M
52W High
9.28 -53.12%
52W Low
1.43 203.22%
Volatility
24.21% 11.50%
ATR (14)
0.85
RSI (14)
29.49
Beta
0.10
Rel Volume
6.98
Avg Volume
71.90K
Volume
501,576
Perf Week
-35.07%
Perf Month
-42.84%
Perf Quarter
-17.63%
Perf Half Y
33.88%
Perf YTD
40.95%
Perf Year
60.74%
Perf 3Y
174.98%
Perf 5Y
114.93%
Perf 10Y
19.35%
Prev Close
8.49
Price
4.35
Change %
-48.76%
Date Action Analyst Rating Change Price Target Change
Nov-12-12Reiterated UBS Neutral $6.50 → $5
Feb-01-11Reiterated UBS Neutral $8 → $6.50
Dec-16-10Downgrade UBS Buy → Neutral $10 → $8
Aug-17-10Reiterated UBS Buy $11 → $10
Aug-17-10Reiterated Morgan Joseph Buy $15 → $10
Aug-17-10Downgrade Jefferies Buy → Hold $13 → $5.50
May-14-10Reiterated Morgan Joseph Buy $21 → $15
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.
FounderMr. A. J. Kazimi MBA
Vice President Accounting & Finance and CFOMr. John Michael Hamm C.M.A.
Vice President of Organizational DevelopmentMr. Todd M. Anthony
Managing Director of Banking & Investor RelationsMr. Adam S. Mostafa